Scopus Biopharma Inc. (SCPS): Price and Financial Metrics
GET POWR RATINGS... FREE!
SCPS Stock Price Chart Interactive Chart >
SCPS Price/Volume Stats
| Current price | $0.38 | 52-week high | $8.03 |
| Prev. close | $0.39 | 52-week low | $0.36 |
| Day low | $0.37 | Volume | 76,100 |
| Day high | $0.41 | Avg. volume | 227,835 |
| 50-day MA | $0.57 | Dividend yield | N/A |
| 200-day MA | $2.20 | Market Cap | 8.02M |
Scopus Biopharma Inc. (SCPS) Company Bio
Scopus BioPharma Inc. develops therapeutics drugs targeting the endocannabinoid system. The company was formerly known as Project18 Inc. and changed its name to Scopus BioPharma Inc. in December, 2017. The company was incorporated in 2017 and is based in New York, New York.
Latest SCPS News From Around the Web
Below are the latest news stories about Scopus BioPharma Inc that investors may wish to consider to help them evaluate SCPS as an investment opportunity.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on FridayGood morning! |
Scopus BioPharma Provides Update Following Annual Meeting of StockholdersOverwhelming Majority of Shares Voted by Unaffiliated Stockholderswere in Favor of Scopus' Director Nominees Lasters’ Ownership Position and Annual Meeting Results are being Challenged in Court Company Believes Ultimate Outcome of Annual Meeting Will Depend on Results of Pending Cases NEW YORK, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: SCPS) (“Scopus” or the “Company”) today announced that it has filed an amendment to the Current Report on Form 8-K that was filed by the Co |
DR. MORRIS C. LASTER WINS PROXY CONTEST AS STOCKHOLDERS ELECT HIS NOMINEES TO SCOPUS BIOPHARMA INC. BOARD OF DIRECTORSDr. Morris C. Laster ("Dr. Laster"), who, together with other proxy participants, beneficially owns 6,006,000 shares of common stock, par value $0.001, of Scopus BioPharma Inc. (Nasdaq: SCPS) ("Scopus" or the "Company"), announced today that stockholders of the Company have elected Dr. Laster's two director nominees, Mordechai Saar Hacham and Joshua Levine to the Company's Board of Directors at the Company's 2021 Annual Meeting of Stockholders (the "Annual Meeting"). |
Scopus BioPharma Issues Open Letter to Stockholders Detailing Morris Laster’s Campaign Against the CompanyLatest Legal Claims by Laster Actually Call into Question his Stock Ownership Company Urges Stockholders to Vote “FOR ALL” of the Company’s Director Nominees on the WHITE Proxy Card NEW YORK, Dec. 17, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: “SCPS”) today issued a second letter to its stockholders in connection with the Company’s Annual Meeting of Stockholders (the “Annual Meeting”) that will be reconvened on Monday, December 20, 2021 at 11:30 a.m., Eastern time. The record date f |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on WednesdayWe've reached the halfway point of the week and there's no slowing down as we dive into the biggest pre-market stock movers for Wednesday! |
SCPS Price Returns
| 1-mo | -25.46% |
| 3-mo | -45.62% |
| 6-mo | -85.21% |
| 1-year | -94.63% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -76.76% |
| 2021 | -88.98% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...